BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., received a patent covering the formulations used in Elestrin (estradiol gel), which recently was approved to treat moderate to severe vasomotor symptoms associated with menopause, and LibiGel (testosterone gel), which recently moved into Phase III studies for female sexual dysfunction.
Carrington Laboratories Inc., of Irving, Texas, said its subsidiary, DelSite Biotechnologies Inc., was granted U.S. Patent No. 7,202,066, titled "Combination of a Growth Factor and a Protease Enzyme," for an advanced wound healing technology.
Cel-Sci Corp., of Vienna, Va., was issued U.S. Patent No. 7,199,216, titled "Peptide constructs for treating autoimmune and related diseases." The patent covers platform technology that can be used for treating diseases such as autoimmune disease, asthma, allergy and transplant rejection.
Chembio Diagnostics Inc., of Medford, N.Y., received U.S. Patent No. 7,189,522, titled "Dual Path Immunoassay Device," describing a device and method for detection that includes a separate, second flow path for application of the sample material to be tested.
Crucell NV, of Leiden, the Netherlands, was granted a patent covering the manufacturing of influenza vaccines using its PER.C6 cell line technology.